Development of Technology for Obtaining Dry Extract "LEFOSED"

Abstract

For the first time, a technology for obtaining a dry extract of "Lefosed" with sedative activity and meeting the requirements of GF XI from a 4-component collection has been developed. The extraction method was chosen, as well as optimal conditions allowing depleting the raw materials as much as possible and enriching the extract with a complex of biologically active compounds contained in the feedstock. The technological characteristics of the dry extract have been studied and determined, with the aim of its further use as a raw material for the production of finished dosage forms.